peptide 1 glp 1 receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Description
, Teladoc Health member Learn how GLP-1s can help you reach your goals Explore educational resources that help you understand how GLP-1 medications work
the active ingredient is tirzepatide, marketed by Eli Lilly

Rousson V, Allignol A, Aurousseau A, et al

Lancet 368 (9548), 16961705
Conclusion The GLP-1 RAs in people with obesity or type 2 diabetes are associated with a significant reduction in all-cause death, alongside an increased risk of pancreatic adverse eventsparticularly acute pancreatitismost pronounced during the first 6 months of treatment
All authors have reviewed the submitted version and agreed to publish the manuscript
